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Dialysate iron therapy: Infusion of soluble ferric
pyrophosphate via the dialysate during hemodialysis
AJAY GUPTA, NEETA B. AMIN, ANATOLE BESARAB, SUSAN E. VOGEL, GEORGE W. DIVINE,
JERRY YEE, and J. V. ANANDAN
Division of Nephrology, Department of Pharmacy Services, and Department of Biostatistics, Henry Ford Hospital,
Detroit, Michigan, USA

Dialysate iron therapy: Infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis.
Background. Soluble iron salts are toxic for parenteral administration because free iron catalyzes free radical generation.
Pyrophosphate strongly complexes iron and enhances iron
transport between transferrin, ferritin, and tissues. Hemodialysis patients need iron to replenish ongoing losses. We evaluated
the short-term safety and efficacy of infusing soluble ferric
pyrophosphate by dialysate.
Methods. Maintenance hemodialysis patients receiving erythropoietin were stabilized on regular doses of intravenous
(i.v.) iron dextran after oral iron supplements were discontinued. During the treatment phase, 10 patients received ferric
pyrophosphate via hemodialysis as monthly dialysate iron concentrations were progressively increased from 2, 4, 8, to 12
mg/dl and were then sustained for two additional months at 12
mg/dl (dialysate iron group); 11 control patients were continued
on i.v. iron dextran (i.v. iron group).
Results. Hemoglobin, serum iron parameters, and the erythropoietin dose did not change significantly from month 0 to
month 6, both within and between the two groups. The weekly
dose of i.v. iron (mean 6 sd) needed to maintain iron balance
during month 6 was 56 6 37 mg in the i.v. iron group compared
with 10 6 23 mg in the dialysate iron group (P 5 0.001).
Intravenous iron was required by all 11 patients in the i.v. iron
group compared with only 2 of the 10 patients receiving 12 mg/dl
dialysate iron. The incidence of adverse effects was similar in
both groups.
Conclusions. Slow infusion of soluble iron pyrophosphate
by hemodialysis may be a safe and effective alternative to the
i.v. administration of colloidal iron dextran in maintenance
hemodialysis patients.

Iron deficiency is the most common nutritional problem worldwide, causing iron-deficiency anemia in 500 to
600 million people [1, 2]. Iron deficiency is associated
Key words: dialysis, iron supplementation, renal toxicity, colloidal iron
dextran, erythropoietin, anemia.
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with prematurity and low birth weight during pregnancy,
defects in cognitive and psychomotor development during childhood, and impaired work capacity in adulthood
[3–8]. Oral iron supplementation programs have failed
primarily because of noncompliance in addition to gastrointestinal adverse effects [9]. As an adjunct or alternative to the oral route, iron has been administered
parenterally for more than 100 years [10]. Soluble iron
compounds are considered too toxic for parenteral administration, as ionization of soluble iron salts liberates
free iron, which catalyzes free radical formation and lipid
peroxidation [11, 12]. The colloidal iron compounds used
for parenteral administration such as iron dextran, saccharate, or gluconate are also associated with serious
side-effects, including hypotension and anaphylactoid reactions [13]. The toxicity of these compounds may be
secondary to liberation of free iron caused by chemical
interactions in plasma [13] or circulating antidextran antibodies in patients administered repeated doses of iron
dextran [14]. Ferric iron is strongly complexed by pyrophosphate; the log of stability or formation constant
(Kstab) is 22.2 [15]. Pyrophosphate is known to trigger
iron removal from transferrin, enhance iron transfer
from transferrin to ferritin, and promote iron exchange
between transferrin molecules [16–19]. These properties
suggest that ferric pyrophosphate may be suitable for
parenteral administration. Furthermore, ferric pyrophosphate (molecular weight of 745.2) is soluble in water
when the granules have been prepared by chemical reaction with citric acid and sodium hydroxide.
A majority of maintenance hemodialysis patients
treated with erythropoietin become iron deficient and
need i.v. iron supplementation to maintain optimal iron
balance [20]. In hemodialysis patients, small water-soluble molecules can be directly infused into the circulation
by their addition to the dialysate solution [21]. We have
previously demonstrated that ferric pyrophosphate is
transported from the dialysate to the blood compartment
during simulated, in vitro hemodialysis (A. Gupta, un-
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published data). The goal of this study was to determine
whether infusion of soluble ferric pyrophosphate by dialysis (dialysate iron therapy) is safe and could obviate the
need for oral and intravenous (i.v.) iron in maintenance
hemodialysis patients.
METHODS
Study design
Informed consent was obtained from 24 patients with
end-stage renal disease receiving maintenance hemodialysis for at least three months. The experimental therapy
of ferric pyrophosphate administration by hemodialysis
was compared with the recommended practice of maintenance i.v. iron dextran treatment [20] in this open-label,
single-center clinical study. The study was approved under an Investigational New Drug Application by the
United States Food and Drug Administration and by
the Human Rights Committee at Henry Ford Hospital
(Detroit, MI, USA).
The inclusion criteria for the study were as follows:
male and female patients 18 years of age or older undergoing hemodialysis three times a week and receiving
erythropoietin for the treatment of anemia, transferrin
saturation (TSAT) between 18 and 25% and serum ferritin level between 100 and 200 mg/liter, and a need for
parenteral iron supplementation within a three-month
period prior to enrollment. Patients were excluded if
they maintained adequate iron balance (TSAT more
than 25% and serum ferritin more than 200 mg/liter)
without parenteral iron supplementation or had severe
iron deficiency (TSAT less than 15% and/or serum ferritin less than 50 mg/liter), had a history of clinically significant allergic reaction to iron, had a history of drug
or alcohol abuse within six months prior to enrollment,
had a history of hepatitis B or HIV infection, or were
child-bearing females not willing to use effective birth
control measures.
The study was performed in two phases, a pretreatment (month 0) phase of four weeks, followed by a
treatment phase (month 1 to 6) of 24 weeks. Predialysis
hemoglobin, hematocrit, serum iron, total iron-binding
capacity (TIBC), and ferritin were measured every week
throughout the study. Erythropoietin was administered
intravenously up to three times per week during hemodialysis, and the dose was adjusted every four weeks in
order to maintain hemoglobin levels between 10 and 12
g/dl. Starting in month 0 and during the seven-month
study period, patients were instructed not to take any
oral iron supplements. Throughout the study, all patients
were eligible to receive variable maintenance doses (0,
25, 50, or 100 mg) of supplemental i.v. iron dextran
(INFeDt; Schein Pharmaceutical, Inc., Florham Park,
NJ, USA) once a week during hemodialysis in order to
maintain a predialysis TSAT of more than 20% and

ferritin of more than 100 mg/liter. In all patients, overt
iron deficiency (TSAT less than 20%) was treated with
100 to 200 mg of iron dextran i.v. with each hemodialysis
session, up to a total dose of 400 to 1000 mg at the
discretion of the principal investigator (A.G.). The serum
iron parameters in the last two weeks of the pretreatment
phase were used for comparison with the parameters in
the treatment phase. During the treatment phase, a cohort of patients was assigned to receive iron pyrophosphate in an escalating dose via the dialysate (dialysate
iron group) during every hemodialysis session for a total
of 24 weeks, whereas a control group continued to receive i.v. iron alone (i.v. iron group). If TSAT exceeded
50%, maintenance i.v. and/or dialysate iron supplementation were discontinued.
During the pretreatment phase, one patient died and
one patient was transferred to another dialysis facility.
During the treatment phase, one patient from the dialysate iron group withdrew after only one dialysis session
because of lack of interest. Thus, data are reported on
the 21 patients who completed the study.
Hemodialysis with solutions containing
ferric pyrophosphate
Ferric pyrophosphate complexed with sodium citrate
is soluble in aqueous solutions (ferric pyrophosphate
soluble; Mallinckrodt Inc., St. Louis, MO, USA) [22].
Soluble ferric pyrophosphate was dissolved in purified
water, and this solution was added to a freshly prepared
bicarbonate concentrate solution. Dialysate solutions
containing the desired concentration of soluble ferric
pyrophosphate were generated by the addition of an
appropriately higher concentration of the compound to
the bicarbonate concentrate. A stable and clear dialysate
solution containing up to 71 mg/dl iron as ferric pyrophosphate could be generated using this method. Bicarbonate
concentrate solutions were used within 24 hours of preparation to avoid bacterial growth. Based on previous in
vitro hemodialysis studies using dialysate iron concentrations between 2 and 70 mg/dl (A. Gupta, unpublished
data) and taking patients’ safety into consideration, in
our study, an initial dialysate iron concentration of 2
mg/dl was increased every four weeks to 4, 8, and then
to a maximum of 12 mg/dl, which was then sustained for
two additional months. All patients were dialyzed using
polysulfone membrane filters (F-80t or F-8t; Fresenius
USA, Walnut Creek, CA, USA), and the filters were
reused after heat sterilization. The hemodialysis-related
parameters (mean 6 se) were as follows: dialysate flow
rate, 800 ml/min; blood flow rate, 465.1 6 14.43 ml/min;
dialysis time, 217.5 6 8.1 min; and KT/V, 1.53 6 0.13.
Efficacy parameters
Hemoglobin and hematocrit were measured weekly
by a colorimetric method, and the mean corpuscular
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hemoglobin content of reticulocytes (reticulocyte hemoglobin) was measured at the end of each month using a
flow cytometry method (H-3; Bayer Diagnostics, Tarrytown, NY, USA). Testing for reticulocyte hemoglobin
was not available during months 0 and 1. Serum iron,
TIBC, and ferritin were measured weekly. Serum iron
and TIBC were analyzed by a colorimetric method (Hitachi 747; Boehringer Mannheim Corp., Indianapolis,
IN, USA). Ferritin was analyzed by a chemiluminescent
immunoassay method (ACCESS; Beckman Instruments,
Fullerton, CA, USA) until the end of month 4. The
heterogeneous competitive magnetic separation assay
(HCMSA) using Immuno-1 (Bayer Diagnostics) was
used for the determination of ferritin for the remaining
samples of the study. The two methods give similar values when compared using the “College of American
Pathologists” (CAP) surveys (Dr. James Zazra, Lifechem
Laboratories Inc., Rockleigh, NJ, USA, personal communication). TSAT was calculated as follows:
TSAT (%) 5 [serum iron (mg/dl)/TIBC (mg/dl)] 3 100
Safety parameters
Nutritional status was monitored by recording body
weight at every dialysis session and by monthly serum
albumin, cholesterol, and triglyceride measurements.
Because there is a theoretical risk of ferric pyrophosphate causing hyperphosphatemia and chelation of serum calcium leading to hypocalcemia, serum calcium and
phosphorus were monitored monthly. Serum ferritin was
measured weekly to detect iron overload, defined as
ferritin greater than 800 mg/liter. Patients were closely
monitored to detect signs and symptoms of iron toxicity
(malaise, headache, back pain, flushing, myalgia, arthralgia, vomiting, diarrhea, urticaria, hypotension, respiratory distress, anaphylactoid reactions, and lymphadenopathy).
Statistical analysis
For each study variable, monthly averages and changes
from pretreatment (month 0) to the final observation
period (month 6) were compared between the two
groups by t-test or Wilcoxon rank sum test. The changes
from pretreatment to month 6 were also tested within
each group by paired t-test or Wilcoxon signed rank
test. Analysis was performed using the SAS procedures
TTEST, MEANS, UNIVARIATE and NPAR1WAY
[23]. Sample size was based on the anticipation that a
50% decrease in maintenance iron requirements could
be detected. All results are reported as mean 6 sd unless
otherwise stated, with a P of less than 0.05 considered
statistically significant.
RESULTS
From November 1996 to July 1997, a total of 21 hemodialysis patients were followed. Demographic and con-

Table 1. Characteristics of patients included in the final analysis
Characteristic
N
Gender (male)a
Age (years)b
Race (African American)a
Hypertensiona
Diabetes mellitusa

Dialysate iron

i.v. iron

10
6 (60%)
53.5 6 14.3 (32–82)
9 (90%)
10 (100%)
6 (60%)

11
7 (64%)
58.1 6 1.5 (32–76)
11 (100%)
11 (100%)
7 (64%)

a
Indicates patients with the characteristic; number in parentheses indicates
percent of patients in the group
b
Plus-minus values are means 6 sd, age range is shown in parentheses

comitant disease states of the patients are shown in Table
1. The predominance of African Americans was consistent with the demographics of our dialysis population.
The efficacy parameters are shown in Table 2, whereas
the safety parameters are summarized in Table 3. None
of these variables were statistically different between the
two groups during month 0. Furthermore, there were
no significant differences in hemodialysis prescription or
dialysis adequacy between the two groups in the baseline
or the treatment phase (data not shown).
Efficacy parameters
Whole blood hemoglobin was maintained at a stable
target level in both the groups, without any significant
difference in between the groups (Table 2 and Fig. 1A).
There was no significant change in erythropoietin dose
throughout the study in either group and no significant
difference between the two groups (Table 2 and Fig.
1B). The dose of erythropoietin was increased from 1000
to 4000 units per treatment in the final month for a
patient in the dialysate iron group, when the hemoglobin
declined following an arterial bypass procedure. This led
to an abrupt increase in the mean erythropoietin dose
for the dialysate iron group in the final month of the
study.
Patients in both groups were prescribed 0 to 200 mg
i.v. iron per dialysis session, up to a maximum total dose
of 400 mg per week. Iron balance, as determined by
TSAT and ferritin, was maintained in both groups
throughout the study, with no significant difference in
TSAT (Fig. 2A) or ferritin (Fig. 2B) between the two
groups (Table 2). Reticulocyte hemoglobin, a marker of
iron deficiency, was 28.4 6 2.9 pg in the dialysate iron
group versus 27.0 6 3.5 pg in the i.v. iron group at month
2 (P 5 0.32) and did not change significantly between
the two groups during the course of the treatment phase
of the study (Table 2). The TIBC was significantly higher
in the dialysate iron group compared with the i.v. iron
group in month 6 (P , 0.05), despite no significant differences in iron parameters or the nutritional status of the
two groups.
During month 0, the weekly dose of i.v. iron dextran
in the dialysate iron group was 69 6 28 mg compared with
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Table 2. Summary of efficacy parameters: A comparison of month 6 with pre-treatment (month 0)
Pre-treatment

Parameter

Month 6

Dialysate iron

i.v. iron

Dialysate iron

i.v. iron

10.6 6 0.8
33.4 6 2.4
not done
54 6 20
222 6 44
25 6 7
210 6 89
3990 6 2370
69 6 28

10.1 6 1.1
32.6 6 3.7
not done
53 6 22
193 6 48
27 6 9
213 6 53
5647 6 2519
60 6 47

10.1 6 1.1
32.0 6 3.9
28.8 6 2.0
54 6 14
235 6 57a
24 6 7
155 6 121
4418 6 2299
10 6 23ab

10.1 6 1.4
33.0 6 4.2
28.3 6 3.0
50 6 20
180 6 42
26 6 5
261 6 212
5392 6 2640
56 6 37

Hemoglobin g/dl
Hematocrit %
Retic. hemoglobin pg
Serum iron lg/dl
TIBC lg/dl
TSAT %
Ferritin lg/liter
Erythropoietin dose units/dialysis session
i.v. iron dextran dose mg/week

Plus-minus values are mean 6 sd. Abbreviations are: Retic. hemoglobin, reticulocyte hemoglobin; TIBC, total iron binding capacity; TSAT, transferrin saturation.
a
P , 0.05 when compared to i.v. iron group at month 6
b
P , 0.05 when compared to pre-treatment (month 0)

Table 3. Summary of safety parameters: A comparison of month 6 to pre-treatment
Pre-treatment
Parameter
Albumin g/dl
Cholesterol mg/dl
Triglycerides mg/dl
Dry weight kg
Serum calcium mg/dl
Serum phosphorus mg/dl
Episodes of hypotension during hemodialysis sessions

Month 6

Dialysate iron

i.v. iron

Dialysate iron

i.v. iron

3.8 6 0.4
161 6 20
209 6 140
83.0 6 17.4
9.5 6 0.9
5.5 6 1.5
1.4 6 1.9

3.8 6 0.4
153 6 33
127 6 51
73.3 6 27.3
9.4 6 1.0
5.4 6 1.4
1.7 6 1.9

3.8 6 0.3
160 6 25
166 6 79
78.4 6 19.5
9.1 6 0.7
5.4 6 0.4
2.3 6 2.7

3.7 6 0.5
136 6 26a
131 6 49
69.5 6 22.6
8.9 6 0.7
5.3 6 1.9
3.0 6 2.5

Plus-minus values are mean 6 sd.
a
P , 0.05 when compared to i.v. iron group pretreatment

60 6 47 mg in the control group. Despite no significant
differences in hemoglobin, TSAT, ferritin, and erythropoietin dose between the two groups, the requirements
for i.v. iron dextran were significantly reduced during
the treatment phase in the dialysate iron group (Fig. 1C).
The decrease in i.v. iron requirements in the dialysate
iron group was accompanied by a concentration-dependent transfer of iron from dialysate to the blood compartment, as demonstrated by an increase in postdialysis
TSAT from 31.7 6 6.8% on 2 mg/dl to 54.7 6 9.9% on
8 mg/dl and 71.8 6 13.4% on 12 mg/dl iron concentration
(Fig. 3A). The increment in TSAT postdialysis remained
constant when dialysate iron concentration was maintained at 12 mg/dl for three months. Although we had
not planned to routinely monitor the decline in serum
iron parameters following dialysis, in one of these patients, a rapid decline in the TSAT and serum iron concentration occurred over one hour, following the end of
a hemodialysis session (Fig. 3B).
Safety parameters
There was no evidence of pulmonary or tracheobronchial toxicity by history or physical examination at the
end of the study. Hypersensitivity reactions were not
encountered in either group. Overt anemia requiring
blood transfusions developed because of excessive gas-

trointestinal blood loss in one of the i.v. iron group patients. Two patients in the dialysate iron group required
blood transfusions, one following coronary artery bypass
surgery and the other following the amputation of a
lower extremity. None of the patients exhibited evidence
of iron overload on clinical or laboratory testing. Postdialysis TSAT was monitored considering the potential
toxicity of free plasma iron if the binding capacity of
transferrin was exceeded. In 6 of the 10 patients in the
dialysate iron group, there were 12 instances when the
postdialysis TSAT exceeded 90%, with no associated
signs or symptoms of iron toxicity. On three occasions
in three different patients, the TSAT immediately postdialysis ranged from 100 to 109%. None of these patients
exhibited any signs or symptoms of iron toxicity during
these occurrences. The nutritional parameters were unchanged for the duration of the study. Serum calcium
and phosphorus were not significantly altered when comparing month 0 to month 6. Predialysis and postdialysis
blood pressures were not significantly different between
the two groups at any time during the study (data not
shown). Hypotension, as defined by systolic blood pressure of less than 100 mm Hg or diastolic blood pressure
less than 60 mm Hg, occurred with equal frequency in
the two groups (Table 3).
Febrile reactions during hemodialysis secondary to ex-

cessive bacterial content of the dialysate were not observed in either group, and there was no evidence for
bacterial overgrowth in iron-containing bicarbonate concentrates. Iron-containing dialysis solutions did not have
any adverse effect on dialyzer reuse or hemodialysis
equipment, including the sensors and dialysis tubing.
DISCUSSION
Soluble iron salts have hitherto been considered too
toxic for parenteral administration because the free iron
catalyzes formation of oxygen free radicals. We have
demonstrated that soluble ferric pyrophosphate can be
infused directly into the circulation by dialysis without
any apparent toxicity. No short-term adverse effects
were noted, even on occasions when the postdialysis
TSAT ranged between 90 and 108% while patients were
dialyzed against a dialysate iron concentration of 12
mg/dl. This may be related to the high affinity of iron
for pyrophosphate that is of the same order of magnitude
as the affinity of iron for transferrin. Therefore, ferric
pyrophosphate is a stable molecule that does not ionize
readily (pKA 22.2), resulting in negligible release of free
iron, even when the binding capacity of transferrin is
exceeded. Studies with another metal pyrophosphate
complex, stannous pyrophosphate, have reported immediate toxic effects, presumably from binding of pyrophosphate moiety to calcium in the blood [24]. Hypocalcemia
was not observed in patients receiving ferric pyrophosphate, as the ferric ion is more strongly complexed by
pyrophosphate than is the stannous ion (pKi approximately 5) or the calcium ion (pKi approximately 5 to 8)
[25, 26].
The colloidal iron compounds are processed in the
reticuloendothelial system before iron is released into
the circulation. On the other hand, pyrophosphate moiety in circulating ferric pyrophosphate is directly able to
trigger iron transfer to transferrin, between transferrin
molecules and between transferrin and ferritin [16–19]
without the need for prior processing by the reticuloendothelial system. In this respect, metabolism of ferric
pyrophosphate resembles physiological processing of
iron delivered into the circulation after absorption by
the gut. The differences in metabolism of soluble and
colloidal iron compounds may be responsible for the
divergent trends in serum ferritin concentration during
the course of the study (Fig. 2B). With the maximum
dialysate concentration of ferric pyrophosphate tested,
the TSAT increased from a predialysis level of 23.6 6
7.1% to 74.2 6 17.2% at the end of hemodialysis and
returned to the predialysis levels within 48 hours. This
decline in TSAT following infusion of ferric pyrophosphate is much more rapid compared with when 50 or
100 mg of i.v. iron dextran is administered (A. Besarab,
unpublished data). The mean weekly i.v. iron require-

Fig. 1. Whole blood hemoglobin (A) and erythropoietin dose per hemodialysis session (B) three times a week remained stable during the
course of the study (mean 6 SE). Symbols are: (d) dialysate iron group;
(n) i.v. iron group. The average weekly intravenous iron dose (C) was
similar in the two groups during the pretreatment phase (month 0).
During the treatment phase (month 1 to 6), patients receiving dialysate
iron had a significantly decreased requirement for i.v. iron compared
with the group receiving i.v. iron alone. *P , 0.05, †P , 0.003, dialysate
iron group vs. i.v. iron group; ‡P , 0.003, pretreatment vs. month 6
within the dialysate iron group.
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Fig. 2. Predialysis serum transferrin saturation (A) and serum ferritin
(B). There was no significant difference between the two groups. Also,
there was no significant change from baseline over time within each
group. Data are means 6 se. Symbols are: (d) dialysate iron group;
(n) i.v. iron group.

ment was reduced by approximately 40 mg in the dialysate iron group, suggesting that approximately 10 to 15
mg of iron are delivered via the dialysate during each
hemodialysis.
It is estimated that nearly two thirds of the maintenance hemodialysis population in the United States is
receiving i.v. iron dextran (Amgen Inc., Thousand Oaks,
CA, USA), the only iron compound available for parenteral administration in the United States at this time.
Furthermore, the use of i.v. iron is expected to increase
following the recommendations by the National Kidney

Fig. 3. Postdialysis serum transferrin saturation (TSAT) indicated a
concentration-dependent increase as dialysate iron concentration was
increased from 2 to 12 mg/dl, and TSAT remained stable during the
last three months when the dialysate iron concentration was maintained
at 12 mg/dl (A). In a patient, TSAT and serum iron were measured
over one hour, following completion of a dialysis session using 12 mg/dl
dialysate iron; a rapid decline in TSAT and serum iron was noted (B).
Symbols are: (d) dialysate iron group; (.) serum iron (mg/dl); (j)
transferrin saturation (%).

Gupta et al: Dialysate iron therapy

Foundation-Dialysis Outcome Quality Initiative [20]. Intravenous iron dextran therapy is associated with arthralgia–myalgia syndrome in 4.7% and serious or life-threatening reactions in 0.7% of patients [27]. Because acute
reactions can occur after subsequent dosing, a test dose
is recommended before every course of parenteral iron
therapy [27]. Furthermore, iron dextran induced loin and
epigastric pain, or hypotension may interfere with the
dialysis treatment. There is also concern about potential
iron overload with i.v. therapy, leading to increased risk
of infection and possibly cancer [28]. Furthermore, frequent administration of i.v. iron dextran to maintenance
hemodialysis patients may be associated with increased
risk of mortality from all causes and specifically from
infections and cardiac diseases (i.v. iron dosing patterns
and mortality; abstract; Collins et al, J Am Soc Nephrol
9:205A, 1998).
This study demonstrated that transfer of soluble ferric
pyrophosphate into the circulation by the process of hemodialysis is effective in maintaining iron balance. Although the actual amount of iron transferred by hemodialysis was not measured, it was sufficient to maintain an
iron balance in 8 of the 10 patients, without an additional
need for oral or i.v. iron supplementation. The two patients who required additional iron had an interruption
in their dialysate iron therapy because of hospitalization
and suffered excessive iron losses consequent to surgery.
This suggests that dialysate iron therapy may be able to
maintain iron balance in the majority of hemodialysis
patients and thereby forego any adjunctive oral or i.v.
iron supplementation. However, in some patients, particularly when there is excessive blood loss, additional oral
or i.v. iron supplements may be required. Dialysate iron
use is likely to significantly decrease the need for i.v.
iron in maintenance hemodialysis patients. In addition
to the indirect cost associated with morbidity and hospitalizations, the direct cost of i.v. iron administration adds
significantly to the hemodialysis cost. A recent pharmacoeconomic analysis of anemia management in maintenance hemodialysis patients showed that optimal treatment with i.v. iron can reduce the dose of erythropoietin
by 35%, but the estimated cost savings were largely offset
by the cost of i.v. iron [29]. The cost of ferric pyrophosphate is only a small fraction of the cost of iron dextran.
Intravenous iron supplementation is often required for
the treatment of iron deficiency in chronic peritoneal
dialysis patients receiving erythropoietin [30]. Preliminary studies have shown that serum iron levels could be
normalized in iron-deficient rabbits when acute peritoneal dialysis was performed using ferric pyrophosphate
fortified dialysis solution (A. Gupta, unpublished data).
Therefore, dialysate iron therapy also holds promise for
peritoneal dialysis patients.
In the general population, oral iron supplementation
programs have failed because of noncompliance [9]. The
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side-effects and expense associated with i.v. or intramuscular colloidal iron compounds have limited their application. The safety and efficacy of slow ferric pyrophosphate infusion by hemodialysis suggest feasibility of
parenteral administration of this compound to nondialysis patients, although this merits further investigation.
Water solubility and the relatively small molecular
weight of ferric pyrophosphate, compared with colloidal
iron compounds, suggest that it may be suitable for use
in transdermal or subcutaneous delivery systems. The
feasibility of administering ferric pyrophosphate to nondialysis patients by the parenteral route needs to be
determined by further elucidation of its ferrokinetics
and metabolism, including transfer of iron to transferrin,
assessment of direct uptake by the tissues, and safety
when the iron-binding capacity of transferrin is exceeded.
In conclusion, we have demonstrated that iron can be
infused into the circulation by the process of dialysis
when ferric pyrophosphate is added to the hemodialysis
solution. A dialysate iron concentration of 12 mg/dl was
found to be safe, and the amount of iron transferred
was sufficient to maintain iron balance in a majority of
maintenance hemodialysis patients, thereby significantly
reducing the requirements for i.v. iron supplementation.
This novel method of iron administration to hemodialysis patients merits further investigation to determine its
long-term safety and efficacy.
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